Jennifer West

Jennifer West

Auto-generated profile, based on publicly available information

Jennifer West

School of Science, Faculty of Science, Medicine & Health, Molecular Horizons Research Institute, University of Wollongong, Wollongong, NSW, Australia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2021 in Science Advances
Verified
Journal Article
Open access
JWJennifer West
Jennifer West
SSSandeep Satapathy
Sandeep Satapathy
DWDaniel R. Whiten
Daniel R. Whiten
MKMegan Kelly
Megan Kelly
Nicholas GeraghtyNicholas Geraghty
Nicholas Geraghty
Mark R. WilsonMark R. Wilson
Mark R. Wilson
Neuroserpin preferentially inhibits amyloid formation; a 14-mer region in neuroserpin is implicated in binding to amyloid.

17 July 2026 in Nature Communications
Verified
Journal Article
Open access
RDRoger B. Dodd
Roger B. Dodd
MEMasahiro Enomoto
Masahiro Enomoto
YZYe Zhou
Ye Zhou
KSKanayo Satoh
Kanayo Satoh
YZYalun Zhang
Yalun Zhang
PGPeter St George-Hyslop
Peter St George-Hyslop
Mechanisms linking CD33 variants to Alzheimer Disease (AD) are poorly defined. Here, we combine structural, cellular, and genetic analyses to delineate how the CD33 M splice isoform, upregulated in carriers of CD33 risk alleles, modulates microglial function. We show that CD33 M ectodomain dimerizes, enabling binding of large multi-sialylated molecules. We demonstrate that another AD risk protein - clusterin (CLU) ± Aβ oligomers (but not ApoE) binds with nanomolar avidity to CD33 M , but not CD33 m . We show that in human monocytes CD33 M :CLU binding induces CD33 M ITIM phosphorylation, recruits SHP-1, suppresses Aβ phagocytosis, and impairs clearance of amyloid plaques. We identify a soluble CD33 M ectodomain fragment (sCD33 M ) - absent from CD33 m -expressing cells - which could contribute to the role of CD33 M in AD. Genetic analyses confirm that CD33:CLU interaction modulates amyloid burden, cognition, and disease risk. These findings define a mechanistic CLU:Aβ:CD33 M axis, highlighting CD33 M dimerization and ligand-binding sites as potential therapeutic targets.